Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1975 Aug;2(4):345–349. doi: 10.1111/j.1365-2125.1975.tb02782.x

Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay.

J D Robinson, B A Morris, G W Aherne, V Marks
PMCID: PMC1402591  PMID: 1233994

Abstract

1. Serum concentrations of phenytoin were studied by radioimmunoassay in five normal volunteers following a single oral dose of phenytoin sodium (100 mg). 2. Two distinct peaks were found at 2.5-3.5 and 10-12 h after ingestion. Maximum serum concentrations ranged from 1.56 mug/ml. The mean plasma half-life of the drug under these conditions was 9.81 +/- 0.66 (s.e. mean) hours.

Full text

PDF
345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
  2. BUCHTHAL F., SVENSMARK O., SCHILLER P. J. Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960 Jun;2:624–630. doi: 10.1001/archneur.1960.03840120030004. [DOI] [PubMed] [Google Scholar]
  3. Cook C. E., Kepler J. A., Christensen H. D. Antiserum to diphenylhydantoin: preparation and characterization. Res Commun Chem Pathol Pharmacol. 1973 May;5(3):767–774. [PubMed] [Google Scholar]
  4. Glazko A. J., Chang T., Baukema J., Dill W. A., Goulet J. R., Buchanan R. A. Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration. Clin Pharmacol Ther. 1969 Jul-Aug;10(4):498–504. doi: 10.1002/cpt1969104498. [DOI] [PubMed] [Google Scholar]
  5. Kutt H., Louis S. Anticonvulsant drugs. I. Patho-physiological and pharmacological aspects. Drugs. 1972;4(3):227–255. doi: 10.2165/00003495-197204030-00003. [DOI] [PubMed] [Google Scholar]
  6. Lund L., Alvan G., Berlin A., Alexanderson B. Pharmacokinetics of single and multiple doses of phenytoin in man. Eur J Clin Pharmacol. 1974;7(2):81–86. doi: 10.1007/BF00561319. [DOI] [PubMed] [Google Scholar]
  7. Marks V., Lindup W. E., Baylis E. M. Measurement of therapeutic agents in blood. Adv Clin Chem. 1973;16:47–109. doi: 10.1016/s0065-2423(08)60344-3. [DOI] [PubMed] [Google Scholar]
  8. Marks V., Morris B. A., Teale J. D. Radioimmunoassay and saturation analysis. Pharmacology. Br Med Bull. 1974 Jan;30(1):80–86. doi: 10.1093/oxfordjournals.bmb.a071172. [DOI] [PubMed] [Google Scholar]
  9. Papadopoulos A. S., Baylis E. M., Fry D. E., Marks V. A rapid micro-method for determining four anti-convulsant drugs by gas-liquid chromatography. Clin Chim Acta. 1973 Oct 12;48(2):135–141. doi: 10.1016/0009-8981(73)90358-6. [DOI] [PubMed] [Google Scholar]
  10. Robinson J. D., Morris B. A., Marks V. Development of a radioimmunoassay for etorphine (preliminary communication). Res Commun Chem Pathol Pharmacol. 1975 Jan;10(1):1–8. [PubMed] [Google Scholar]
  11. Tigelaar R. E., Rapport R. L., 2nd, Inman J. K., Kupferberg H. J. A radioimmunoassay for diphenylhydantoin. Clin Chim Acta. 1973 Jan 24;43(2):231–241. doi: 10.1016/0009-8981(73)90456-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES